TY - JOUR
T1 - Dose-related activity of stavudine in patients infected with human immunodeficiency virus
AU - Petersen, Eskild A.
AU - Ramírez-Ronda, Carlos H.
AU - Hardy, W. David
AU - Schwartz, Robert
AU - Sacks, Henry S.
AU - Follansbee, Stephen
AU - Peterson, Dolores M.
AU - Cross, Anne
AU - Anderson, Robert E.
AU - Dunkle, Lisa M.
PY - 1995/3
Y1 - 1995/3
N2 - In a multicenter, randomized, open-label, dose-ranging study to determine the relative effects of three dose levels of stavudine on CD4 lymphocyte count, weight gain, and hematologic variables in patients infected with human immunodeficiency virus (HIV), 152 patients with CD4 lymphocyte counts ≤600/mm3 received stavudine at 0.1 mg/kg/day (n = 51),0.5 rug/kg/day (n> = 53), or 2.0 rug/kg/day (n = 48). The study was designed to evaluate the activity of stavudine after 10 weeks of therapy and permitted extended dosing and follow-up for long-term safety. A significant dose effect on increases in CD4 lymphocyte counts and declines in HIV titer in peripheral blood mononuclear cells was observed. Stavudine was well-tolerated; the onlydose-related, dose-limiting adverse event was peripheral neuropathy, which usually was reversible. In this trial, the most favorable therapeutic index was seen at 0.5 rug/kg/day.
AB - In a multicenter, randomized, open-label, dose-ranging study to determine the relative effects of three dose levels of stavudine on CD4 lymphocyte count, weight gain, and hematologic variables in patients infected with human immunodeficiency virus (HIV), 152 patients with CD4 lymphocyte counts ≤600/mm3 received stavudine at 0.1 mg/kg/day (n = 51),0.5 rug/kg/day (n> = 53), or 2.0 rug/kg/day (n = 48). The study was designed to evaluate the activity of stavudine after 10 weeks of therapy and permitted extended dosing and follow-up for long-term safety. A significant dose effect on increases in CD4 lymphocyte counts and declines in HIV titer in peripheral blood mononuclear cells was observed. Stavudine was well-tolerated; the onlydose-related, dose-limiting adverse event was peripheral neuropathy, which usually was reversible. In this trial, the most favorable therapeutic index was seen at 0.5 rug/kg/day.
UR - http://www.scopus.com/inward/record.url?scp=0028910235&partnerID=8YFLogxK
U2 - 10.1093/infdis/171.Supplement_2.S131
DO - 10.1093/infdis/171.Supplement_2.S131
M3 - Article
C2 - 7861018
AN - SCOPUS:0028910235
SN - 0022-1899
VL - 171
SP - S131-S139
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
ER -